Il danno d’organo provocato dal Virus C Gloria Taliani 8 Maggio 2014 Malattie Infettive e Tropicali Sapienza Università di Roma Policlinico Umberto I, Roma Seminario Nadir 2014 - Iniziativa resa possibile grazie a fondi istituzionali dell’Associazione Natural History of HCV Infection Acute HCV Resolved 15% Chronic HCV 85% Stable 80% (68%) Cirrhosis 20% (17%) Slowly progressive 75% (13%) HCC Liver failure 25% (4%) Hepatitis C Disease Pathogenesis CD4+ CD8+ Cell killing Cytokines (IL-2, IFN-TNF-a, TGF-PDGF) TGF- Death Kupffer cell Hepatocytes Activation Hepatic stellate cells Fibrosis Influence of HIV-1 replication and its treatment on the liver in HCV coinfection Kim RY and Chung RT GASTROENTEROLOGY 2009;137:795– 814 Advanced Liver Disease • Histologic – Bridging fibrosis • Ishak 3/6-4/6 • Metavir 3/4 – Cirrhosis • Ishak 5/6-6/6 • Metavir 4/4 Ishak KG, et al. J Hepatol. 1995;22:696-699. Bedossa P, et al. Hepatology. 1996;24:289-293. Complications of Advanced Liver Disease • Clinical – Portal hypertension • Thrombocytopenia, varices, nodular liver – Impaired hepatic function • Albumin, bilirubin, INR • Decompensation – – – – Ascites Encephalopathy Variceal hemorrhage Jaundice Sangiovanni A, et al. Hepatology. 2006;43:1303-1310. Cumulative probability of events The long-term outcome of HCV compensated cirrhosis: a 17-yr follow-up of 214 Pts 100 Annual Incidence rate 50 HCC Ascites Jaundice GI bleeding EPS 25 3.9% 2.9% 2.0% 0.7% 0.1% HCC Ascites Jaundice GI bleeding EPS 0 Pts still at risk 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 214 214 214 214 214 196 197 196 198 198 186 182 184 188 190 168 163 164 171 173 153 151 152 160 162 142 142 144 151 152 129 133 134 142 146 116 114 122 129 129 110 105 114 122 122 96 92 100 105 108 89 86 89 94 98 74 74 75 81 84 66 68 69 73 77 57 60 60 64 66 48 55 54 58 59 36 39 40 42 43 Sangiovanni A et al Hepatology 2006 Years Effect of Inflammation on Fibrosis Progression in HCV Patients Change in Fibrosis Score According to Necrosis Score at Baseline Patients, n Mean change in fibrosis score per yr Piecemeal Necrosis Score at Baseline 0-1 2-3 >4 30 66 27 0.05 Ghany MG, et al. Gastroenterol. 2003;124:97-104. 0.19 0.37 Patients Developing Cirrhosis According to Initial Level of Fibrosis Fibrosis Score Description of Fibrosis Patients Progressing to Cirrhosis by Year 10, % ≤ 1.9 (n = 27) None; too mild to alter portal tract size 29.6 2.0-2.9 (n = 28) Portal/periportal ± portalportal bridging 42.9 3.0-3.45 (n = 15) Septal + regions of partial nodular regeneration 100 Yano M, et al. Hepatology. 1996;23:1334-1340. Factors Associated With Advanced Fibrosis • • Retrospective study of 460 pts with chronic hepatitis C (41% F3-4) Multivariate analysis of factors associated with F3-4 Risk Factor Adjusted Odds Ratio (95% CI) 3.444 Age at entry (≥ 60 years) P Value .0334 Duration of infection (≥ 25 years) 1.750 .0378 BMI (≥ 30) 1.917 .0173 2.251 History of diabetes AST (≥ 80 U/L) 4.032 AFP (≥ 15 µg/L) 3.875 Grades 2 and 3 steatosis .0087 .0383 2.790 0.01 Hu S, et al. J Clin Gastro. 2009 .0304 1.0 .0378 15.0 Insulin Resistance Associated With More Rapid Fibrosis Progression in HCV Pts • In 260 HCV-infected subjects, insulin resistance independently associated with stage of fibrosis – OR: 1.3; P < .001 for trend HOMA-IR 5 4 3 2 1 0 F0 F1 F2 Fibrosis Score Hui JM, et al. Gastroenterol. 2003;125:1695-1704. F3 F4 Cannabis Use Significantly Associated With Faster Rate of Fibrosis Progression • 270 untreated HCV-infected patients undergoing liver biopsy evaluated for risk factors of rapid fibrosis progression – 52.2% noncannabis users; 14.8% occasional cannabis users; 33.0% daily cannabis users Cannabis Use Odds Ratio of Accelerated Fibrosis Progression Rate* (95% CI) 1.3 Occasional .57 3.4 Daily 0.01 1.0 .005 10.0 *Compared with median progression rate of cohort: 0.074 Metavir U/yr. Hezode C, et al. Hepatology. 2005;42:63-71. P Value Alcohol Consumption Increases Risk of Cirrhosis in HCV Patients 100 Cirrhosis (%) 80 P < .01 P < .01 64 58 60 P < .01 85 40 40 20 0 HCV HCV + alcohol* 31 18 12 6 10 20 30 Years Following Exposure† 40 *Excessive alcohol intake characterized as > 40 g/day for women and > 60 g/day for men. †Duration of exposure defined as either first blood transfusion before 1990 or from the year of initial intravenous drug use. Wiley TE, et al. Hepatology. 1998:28:805-809. 100 % Survival at 1 year 80 % 45 % 1-year mortality rate according to clinical stages Compensated Classification from a systematic review of 118 studies Stage 1 1% No varices No ascites 7% Stage 2 4.4% 3.4% Varices No ascites 4% DEATH Decompensated 6.6% Stage 3 Ascites +/- 20% varices 7.6% Stage 4 Bleeding +/ascites 57% D’Amico G et al J Hepatol 2006 Survival Probability in HCV Patients With Cirrhosis Compensated Survival Probability 100 After first major complication Patients (%) 80 60 40 20 0 0 12 24 36 48 60 72 Mos 84 Patients at Risk 384 376 342 288 236 165 126 79 65 39 21 11 7 4 4 3 96 108 120 52 3 39 2 25 1 Fattovich G, et al, Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology, 1997: 112, , 463-472. Cirrhosis The impact of SVR on histological outcome of HCV-induced cirrhosis Post-treatment Pre-treatment F0 F1 F2 F3 F4 F0 1 2 0 0 0 F1 14 16 7 0 0 F2 7 23 12 2 4 F3 0 5 12 7 4 F4 0 1 2 6 5 Post-treatment specimens were collected a median of 6 months after treatment cessation Comparison of liver fibrosis stage between pre-treatment and post-treatment paired liver biopsy in 126 patients Maylin S et al Gastroenterology 2008 Rate (%) of patients with hystological regression of cirrhosis after the achievement of SVR in HCV-induced disease 96 patients with biopsy-proven cirrhosis (METAVIR score F4); treated with IFN; posttreatment liver biopsy. The median follow-up was 118 months (interquartile range, 86 to 138 months). Eighteen patients had regression of cirrhosis. Mallet V et al Ann Int Med 2008 Cumulative incidence of esophageal varices in 149 IFN ± RBVtreated patients with compensated HCV-induced cirrhosis according to response to therapy Patients still at risk No SVR 115 89 65 35 7 0 SVR 34 30 27 17 7 0 * Years since initiation of antiviral treatment Bruno S, et al Hepatology 2010 Impact of SVR on long-term outcome in 848 patients with HCV-related histologically-proven cirrhosis (stage 1) treated with IFN MT (14 yers FU) (p: 0.001 by log-rank test) 80 60 40 no SVR 20 SVR 0 0 24 48 Patients at risk SVR no SVR 72 96 120 144 months 124 759 119 702 116 634 108 527 70 345 41 207 12 34 liver-related complications 168 % survival to liver-related death % with liver complications 100 (p: 0.001 by log-rank test) SVR 100 no SVR 80 60 40 20 0 0 24 48 72 120 728 115 680 112 629 105 541 Patients at risk SVR no SVR 96 120 144 38 234 11 47 months 66 369 Liver mortality Bruno S et al Hepatology 2007 168 20 10 With SVR 0 0 1 2 3 4 5 6 7 8 9 10 Yrs Hepatocellular Carcinoma (%) Pts at Risk, n Without SVR 405 393 382 363 344 317 295 250 207 164 135 With SVR 192 181 168 162 155 144 125 88 56 40 28 30 Hepatocellular Carcinoma P < .001 20 10 0 With SVR 0 1 2 3 4 5 6 7 8 9 10 Yrs Pts at Risk, n Without SVR 405 390 375 349 326 294 269 229 191 151 122 With SVR 192 181 167 161 152 142 124 86 54 39 27 Van der Meer AJ, et al. JAMA. 2012;308:2584-2593. Liver-Related Mortality or Liver Transplantation P < .001 30 20 10 With SVR 0 0 1 2 3 4 5 6 7 8 9 10 Yrs Pts at Risk, n Without SVR 405 392 380 358 334 305 277 229 187 146 119 With SVR 192 181 168 162 155 144 125 88 56 40 28 Liver Failure (%) All-Cause Mortality P < .001 30 Liver-Related Mortality or Liver Transplantation (%) All-Cause Mortality (%) Survival Outcomes in Pts With CHC and Advanced Fibrosis Liver Failure 30 P < .001 20 10 With SVR 0 0 1 2 3 4 5 6 7 8 9 10 Yrs Pts at Risk, n Without SVR 405 384 361 337 314 288 259 216 184 143 113 With SVR 192 180 166 160 152 141 123 88 56 40 28 Achieving Sustained Virologic Response: Impact on Long-Term Outcomes in HIV/HCV-Coinfection GESIDA 3603 Cohort: 711 pts treated for HCV Achieved SVR Did not achieve SVR 4.33 Long-Term Outcome Rate (per 100 person/years) (3.16,5.8) 3.12 (2.16,4.37) 1.65 (0.98,2.16) 0.46* 0.23† (0.06,1.65) (0.01,1.27) 0.23‡ (0.01,1.27) 0 (0,0.84) Overall Mortality 1.02 0.83 Liver-Related Mortality Liver Decompensation Hepatocarcinoma 0§ (0.44,1.70) 0.23 (0.01,1.27) (0,0.84) Liver Transplantation *P=0.003, †P=0.028, ‡P<0.001, and §P=0.034 versus not attaining a sustained virologic response. n=711 HIV/HCV-coinfected patients receiving interferon (peg or conventional) + ribavirin. Berenguer J. et al. Hepatology 2009. 0.93 (0.50,1.82) (0.38,1.58) New AIDS Conditions Event-free survival according to response to therapy in 102 patients with HCV-induced cirrhosis and portal hypertension (stage 2) % of Patients Without Events Liver-related 100 80 SVR (16 pts) 60 40 NR (86 pts) 20 p= 0.006 by log rank test 0 0 6 12 18 24 30 36 Months 42 48 54 60 Di Marco V et al J Hepatol 2007 Cumulative probability of survival of SVRs versus Non SVRs and controls in patients with decompensated HCV-induced cirrhosis Cumulative probability of survival 1 SVR 0,9 NonR Ctrl 0,8 p= 0.07 0,7 0,6 0,5 0 6 12 18 24 30 36 42 months Iacobellis A et al J Hepatol 2007 Factors Associated With Greater Benefit or Greater Risk of Treatment in Cirrhotics Factors Associated With Greater Benefit of Therapy Factors Associated With Greater Risks of Therapy ↓ Child-Pugh score ↑ Child-Pugh score ↓ MELD score ↑ MELD score ↑ Platelet count ↓ Platelet count ↑ Albumin level ↓ Albumin level ↓ Age ↑ Age Deaths and AEs in the first 6 month of follow-up according to treatment or not OR=2.4 (1.02 – 5.77) 20 OR=0.7 15 OR=0.6 10 OR=2.9 OR=1.2 OR=0.6 OR=1.9 OR=0.9 5 0 Ascites EPS Bleeding HCC I nfection Severe infection Deaths Deaths related to infection Iacobellis A et al J Hepatol 2007 HCC occurrence in patients with HCV-related cirrhosis according to SVR Singal AK Clin Gastroenterol Hepatol 2010 Meta-analysis: Risk of HCC in HCV Pts With Advanced Fibrosis Following SVR • 1000 patients with bridging fibrosis or cirrhosis who achieved SVR following IFN-based HCV therapy followed for median of 5.7 yrs • Cirrhotics at greatest risk of HCC following SVR Cumulative HCC Occurrence (%) 12 10 Cirrhosis 8 6 8-Yr HCC Rate, % (95% CI) 8.5 (5.8-11.2) P = .064 4 Bridging Fibrosis 2 0 0 1 2 3 4 Yrs 5 Van der Meer AJ, et al. AASLD 2013. Abstract 143. 6 7 8 1.8 (0-4.3) Age as a Risk Factor for HCC Following SVR in HCV Pts With Advanced Fibrosis • HCC risk increased with age; highest for those > 60 yrs 8-Yr HCC Rate, % (95% CI) Cumulative HCC Occurrence (%) 12 12.2% (5.3-19.1) > 60 yrs of age 45-60 yrs of age < 45 yrs of age 10 8 6 9.7% (5.8-13.6) P = .006 4 2.6% (0-5.5) 2 0 0 1 2 3 4 Yrs 5 6 7 8 Van der Meer AJ, et al. AASLD 2013. Abstract 143. Reproduced with permission. Cirrhosis: A Continuous Spectrum of Disease ESLD Child-Pugh B Portal hypertension – high risk Cirrhosis – treatment candidate Liver disease is not optimally represented by Child-Pugh stage (A, B, or C) or MELD score Severity of Disease Increases Need for HCV Therapy but Also Impairs Response May not need immediate treatment BUT • Easier to treat • High likelihood of response Mild disease Greater need for treatment BUT • Response to current IFN-based therapy may be impaired Advanced disease/ cirrhosis DAA Classes and Subclasses: antiviral potency and resistance barrier according to HCV genotype Drug Class Subclass 1st Generation first wave i.e. Telaprevir/Boceprevir Protease inhinbitors 1st Generation 2nd wave i.e. Faldaprevir/Simeprevir/ 2nd Generation MK5172 § 1st Generation Daclatasvir Ledipasvir ABT 267 NS5a Inhibitor 2nd Generation MK 8742 GS 5816 NN Polymerase Inhibitors ABT 333 GS 9669 Deleobuvir Nucleos/tides Polymerase inhibitors 2nd Generation : Sofosbuvir 33 High Moderate Low Very low 1b 1a 2 3 4 Seminario Nadir 2014 - Iniziativa resa possibile grazie a fondi istituzionali dell’Associazione